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Abstract
Introduction: The article discusses the issues of the long-term glucocorticosteroid therapy in children with nephrotic 
syndrome that results in severe adverse side effects.
Methods: This retrospective study included 89 case reports of patients with nephrotic syndrome, aged 1–18, who 
received treatment at Voronezh Regional Pediatric Hospital №1 in 1999–2014. The children’s BMI Z-score was cal-
culated from neasured height and weight. The authors considered therapeutical complications revealed through clini-
cal-laboratory and instrumentation examination.
Results and discussion: Long-term administration of glucocorticosteroids in patients with steroid-dependent nephrotic 
syndrome caused overweight and obesity. The patients who had received glucocorticosteroids for 6 months prior to 
the examination were overweight or obese (78%), had reactive pancreatitis (72%), leukemoid reactions (67%), liver 
damage (50%), Cushing’s syndrome (44%), chronic gastroduodenitis (33%), hyperglycemia (11%), arterial hyperten-
sion (6%), or infectious diseases (6%). The children observed during the period of prolonged remission of nephrotic 
syndrome had neither overweight, nor obesity or growth failure; signs of chronic gastroduodenitis were observed in 
15% of the children.
Conclusion: The long-term glucocorticosteroid therapy in children with nephrotic syndrome caused the excess body 
weight or obesity and gastro-intestinal disorders. So, proton pump inhibitors should be applied simultaneously with 
glucocorticosteroids to prevent gastro-intestinal disorders.
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Introduction
Nephrotic syndrome is a clinical symptom complex 
characterized by proteinuria of >40 mg/m2/h, a decreased 
blood albumin level to <25 g/l, hyperlipidemia and swel-
ling development (Obukhova and Dlin 2014). The inci-
dence of this diseases in the pediatric population is 2–7 
primary cases per 100 000 children a year; this disease 
may be idiopathic or secondary (in the presence of syste-
mic diseases of the connective tissue, drug administration 
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and other pathologies) (Clinical recommendations on me-
dical care for children with nephrotic syndrome).
The idiopathic nephrotic syndrome (INS) is the most 
common in children. The onset of the disease at the age 
of 4–6 is characterized by the most favourable course and 
an adequate response to the steroid therapy. Minimal glo-
merular alterations, when light microscopy detects insig-
nificant changes or lack of any, appear to be a morpho-
logical substrate of this clinical course. Focal-segmental 
glomerular sclerosis is more common in children experi-
encing the first occurrence of nephrotic syndrome at the 
age of 6 (up to 45% of cases); other types of the disease 
are less common (Clinical recommendations on medical 
care for children with nephrotic syndrome).
According to the International Study of Kidney Dis-
ease in Children (ISKDC) recommendations, administra-
tion of glucocorticosteroids (GCS) is indicated to all chil-
dren with INS (Beck et al. 2013). The standard regimen 
of the glucocorticosteroid therapy includes administration 
of prednisolone at a dose of 60 mg/m2/day (no more than 
60 mg/day) for 4–6 weeks, followed by a hormone pre-
scribed in the alternating regimen, every other day, at a 
single dose of 40 mg/m2 (maximum 40 mg/48 h) for 4–6 
weeks with gradual dose reduction by 5 mg (10 mg/m2) 
once a week until total discontinuation of the drug. The 
entire duration of the glucocorticosteroid therapy should 
be of no less than 4–5 months (Lombel et al. 2013, Pas-
ini et al. 2015). The alternating regimen (administration 
of the drug every other day) is suggested to support re-
mission, since this regimen has a less negative impact on 
the child growth and extends the remission of the disease 
(Broyer et al. 1992).
The nephrotic syndrome is divided into steroid-sen-
sitive nephrotic syndrome (SSNS) and steroid-resistant 
nephrotic syndrome (SRNS) depending on the response 
to the conventional therapy. In SSNS, the remission is 
usually achieved within 2–4 weeks, in some patients – by 
the 6th-8th week, and only in 4% of children – in 12 weeks 
after the onset of treatment. If there is no remission in 8 
weeks after the start of prednisolone administration, then 
SRNS is diagnosed (Obukhova and Dlin 2014). Approx-
imately 80–90% of children respond to the corticosteroid 
therapy appropriately and have a favourable prognosis; 
but 50–60% of patients have either frequent disease re-
currences, or develop a steroid-dependent variant of the 
SSNS, which is termed steroid-dependent nephrotic syn-
drome (SDNS) (Obukhova and Dlin 2014). Most children 
with the relapsing course of the disease will afterwards re-
spond with a complete remission to corticosteroids, and a 
long-term prognosis in this group of patients is favourable 
(Hjorten et al. 2016). The recurrent attacks, steroid-de-
pendence and steroid-toxicity appear to be indications for 
administration of the immunosuppressive therapy with 
cytostatics, alkylating agents or preparations of monoclo-
nal antibodies (rituximab) (Obukhova and Dlin 2014).
Children with frequently relapsing nephrotic syndrome 
(FRNS) and SDNS require a long-term corticosteroid 
therapy, which results in the development of severe side 
effects, including growth failure, behavioral disorders, 
obesity, Cushing’s syndrome, hypertension, visual im-
pairment, impaired glucose tolerance, decreased bone 
mineral density and other disorders (Obukhova and Dlin 
2014). The number of adverse side effects (ASE) is con-
sidered to be the highest when administering glucocorti-
costeroids at high doses considerably exceeding physio-
logical doses (Landyshev 2014). Moderate and high doses 
of corticosteroids administered for anti-inflammatory and 
immunosuppressive purposes are stated to be >0.5–0.75 
mg/kg/day relating to prednisolone (Landyshev 2014, 
Simmonds et al. 2010).
Side effects of the glucocorticosteroid therapy de-
pend on both – dosage and duration of treatment, and 
an individual patient’s sensitivity. The impact of various 
schemes of the glucocorticosteroid therapy on the risk of 
the development of nephrotic syndrome and the adverse 
event detection frequency have been studied in Hahn et 
al. (2015), and no significant differences in the risk of ad-
verse events were found between long-term treatment and 
2–3-month courses of prednisolone administration (Hahn 
et al. 2015).
Methods
This retrospective study included 89 case reports of pa-
tients with nephrotic syndrome, aged 1–18; all the pa-
tients received treatment at Voronezh Regional Pediatric 
Hospital №1 in 1999–2014.
To perform the comparative evaluation of the parameters 
of body length, body weight and body mass index (BMI), 
Z-score was calculated following the method suggested by 
the World Health Organization (WHO) using WHO An-
throPlus software (WHO growth reference 5–19 years).
NS and a clinical variation of the disease were deter-
mined as defined in the current clinical recommendations 
(Clinical recommendations on medical care for children 
with nephrotic syndrome). The children having NS were 
given therapy in compliance with the protocol of the ISK-
DC and Federal Clinical Recommendations (Beck et al. 
2013, Clinical recommendations on medical care for chil-
dren with nephrotic syndrome). Relapses of the disease 
were treated with a course of prednisolone (60 mg/m2/
day, three times a day) until 3 normal urinary test results 
were obtained; prednisolone therapy was then continued 
in the alternating regimen (40 mg/m2/48h in a single dose 
for 4–6 weeks) with further dose reduction by 5–10 mg/
week until complete withdrawal of the preparation (Beck 
et al. 2013). When complications of the GCS therapy 
were revealed, the treatment was performed according 
to the clinical recommendations on the management of 
patients (Clinical recommendations on medical care for 
children with nephrotic syndrome).
Statistical analysis was performed using STATISTI-
CA v. 6.0. software (StatSoft, США). Mean values (MV) 
were presented together with the standard deviation (SD). 
The two-tailed Student’s t-test was used to reveal signif-
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icant differences between two independent groups; the 
test was performed under the following condition – the 
compliance between the empirical distribution of Gauss-
ian samples and dispersion equality in the groups. Dis-
persion equality in the groups was tested by F-test. When 
the Gaussian assumption for the values under study were 
rejected, the non-parametric Mann-Whitney U test was 
applied to analyze differences in two groups. These pa-
rameters were described using the median value (25th; 75th 
percentiles). The probability of statistical hypotheses was 
accepted to be at a 5% level of significance.
Results and discussion
The impact of glucocorticosteroids on the physical deve-
lopment of children was assessed on the case reports of 28 
patients who had been receiving the glucocorticosteroid 
therapy during the last 6 months before the examination. 
Twelve patients included in the study had non-frequently 
relapsing steroid-sensitive nephrotic syndrome (SSNS), 
6 patients had frequently relapsing nephrotic syndrome 
(FRNS), and 10 patients had steroid-dependent nephrotic 
syndrome (SDNS). Table 1 presents the characteristics of 
the patients of different groups.
Groups of patients with various clinical forms of NS 
did not differ in age (Table 1). The median age in different 
groups was 6–8.3 years. The children with FRNS, espe-
cially, those with SDNS, had a statistically longer duration 
of the disease, duration of GCS therapy and total cumu-
lative GCS dose compared to the children with non-fre-
quently relapsing nephrotic syndrome. The most signif-
icant differences were obtained in patients with SDNS. 
Those children received long-term treatment with low 
doses of corticosteroids. The patients with frequently re-
lapsing nephrotic syndrome received repeated courses of 
high doses of GCS. No differences were revealed between 
the groups of patients regarding the dose received by the 
children during the last 6 months of the therapy (р=0.306).
All the atients with nephrotic syndrome had body 
length parameters within the normal values of healthy 
children (the mean value of Z-score being 0 and standard 
deviation equalling 1). Mean values of the body length 
were lower in the group of patients with steroid-depend-
ent nephrotic syndrome compared to the children with 
non-frequently and frequently relapsing nephrotic syn-
drome (Fig. 1).
The mean values of BMI were higher in the patients 
with frequently relapsing and steroid-dependent nephrot-
ic syndrome compared to the patients with non-frequently 
relapsing nephrotic syndrome. The most significant devi-
ations of Z-score from the mean values were obtained in 
the group of children dependent on steroids. Long-term 
administration of GCS resulted in overweight and obesity 
in these patients (BMI Z-score >1) (Fig. 2).
A retrospective analysis of other adverse side effects 
(ASE) of the glucocorticosteroid therapy was performed 
in 31 patients with steroid-sensitive nephrotic syndrome. 
The analysis included 16 boys (51.6%) and 15 girls 
(48.4%), aged 3–18; median age (standard deviation, SD) 
was 8.2 (SD - 4.0). Group 1 included 18 children who had 
been receiving GCS for 6 months prior to the hospital ad-
mission; this number also included 4 children with FRNS 
and 3 patients with SDNS. Group 2 included 13 patients 
who had not received GCS for 6 months and longer. All 
the patients of group 2 had non-frequently relapsing ne-
phrotic syndrome, with remission periods up to 13 years.
Most children (21 patients, 68%) were admitted to the 
hospital repeatedly; the total number of hospitalizations 
was 87, 4.1 hospitalizations per one child (Table 2).
Thirty-seven patients (43%) were admitted to the hos-
pital in the relapsing period, 50 patients (57%) – in the 
remission period. Duration of the remission in patients 
from different groups is given in Table 2. Hospital admis-
sion during the period of remission was accompanied by 
a course of GCS therapy in patients of group 1. Patients 
of group 2 admitted during the period of remission did 
not receive GCS. Over the three years of observation, two 
Table 1. Clinical Variations of the Disease and Administered Doses of Glucocorticosteroids in Pediatric Patients with Nephrotic 
Syndrome.
Parameters SSNS FRNS SDNS рn=12 n=6 n=10
Age of children, years 6.0 7.8 8.3
0.515Median value (25; 75) (5.2; 9.6) (5.3; 8.1) (4.6–13.3)
min–max 4.0–14.0 4.2–14.5 3.1–17.4
Duration of the disease, months (mos) 16.0 39 60
0.021Median value (25; 75) (8.8; 32.3) (19.0; 70.0) (29–124.3)
min–max 4.0–43.0 19.0–74.0 7.0–177.0
Duration of GCS therapy, days 270 670 1266
0.005Median value (25; 75) (183; 491.3) (630; 730) (562.3; 2450)
min–max 90–760 518–1185 220–3592
Cumulative dose of GCS, mg/kg 202.6 333.8 518.7
<0.001Median value (25; 75) (154.8; 230.3) (294.2; 361.3) (423.1; 594.7)
min–max 92.8–316.1 286.5–487.7 230–706.4
Dose of GCS during 6 mos, mg/kg 52.3 48.3 55.3
0.306Median value (25; 75) (35.1; 67.9) (35.6; 51.9) (28.3; 130.2)
min–max 13–118.6 26.9–72.7 15–266.5
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patients of group 2 had had one relapse of nephrotic syn-
drome – after remission of 24 and 37 months.
The side effects of the GCS pharmacotherapy were as-
sessed in the patients in all the periods of hospitalizations. 
The following parameters were considered for assessment 
of the adverse side effects: complaints, physical signs of 
Cushing’s syndrome, blood pressure findings, full blood 
count and biochemical assay findings, urinary test find-
ings, results of the kidney and abdominal US examina-
tion, fibrogastroduodenoscopy, and the results of the 
ophthalmological examination. The following parameters 
were assessed: the changes in the general health, devi-
ations from the normal values of the physical develop-
ment parameters and findings of the laboratory and in-
strumentation tests, which appeared in in patients when 
administering the GCS therapy and were observed after 
its completion. Before GCS administration, the children 
had neither gastro-intestinal pathologies, nor obesity; 
their blood pressure did not exceed the 90th percentile of 
the age norm; there were no pathological changes in ei-
ther laboratory, or instrumentation test findings. No other 
pathologies were revealed in the patients included in the 
study, they were not taking other preparations that might 
result in the observed conditions.
Most of the children had several hospitalizations re-
garding nephrotic syndrome; the incidence of ASE was 
considered during all the hospitalizations; the level of 
physical development, the cumulative dose of GCS and 
the clinical variation of the disease were assessed based 
on the findings of the last hospitalization.
The children of group 1 and 2 with non-FRNS received 
lower a cumulative dose of prednisolone and had a short-
er duration of GCS administration than the patients with 
FRNS and SDNS.
ASEs of the corticosteroid therapy were recorded in 17 
patients of group 1 (94.4%). Several ASEs were observed 
in all the patients of group 1. Two children of group 2 were 
diagnosed with diseases that might have resulted from the 
previous GCS therapy; the other children of group 2 had 
no delayed complications of the GCS administration.
Overweight and obesity – either as an autonomous 
complication after the GCS therapy or as a sign of Cush-
ing’s syndrome – were most frequently observed in chil-
dren of group 1. Some children had body weight gain 
within the normal values typical for this age and gender. 
Cushing’s syndrome was diagnosed in cases of specific 
Cushing-type distribution of adipose tissues (in the neck, 
facial, abdominal regions), the thinning of the limbs, skin 
changes, and striae appearance.
No children of short or shorter than medium height 
were revealed (body length Z-score <2). Two patients of 
group 1 in repeated hospitalization during the relapsing 
period of NS had a decreased Z-score of the body length 
within the normal values typical for this age and gender. 
In the further observation period, the body length Z-score 
recovered to reach the previous parameters.
Table 2. Hospitalization of Patients with Steroid Sensitive Nephrotic Syndrome.
Parameters
Group1 (n=18) Group 2 
Non-FRNS (n=13) рNon-FRNS (n=11) FRNS and SDNS (n=7)
Total number of hospitalizations, abs. 43 28 16
Number of hospitalizations per one patient 3.9 4.0 1.2 0.033
Number of hospitalization in the relapsing 
period, abs. (%) 21 (49) 14 (50) 2 (15)
Duration of remission, months M (SD), 
months min – max 
3.1 (2.4) – 60.8 (51.5) 0.0001–10 mon 11 mon–150 mon
Figure 1. Z-score of the body length in patients with differ-
ent clinical variations of nephrotic syndrome (1 – SSNS, 2 
– FRNS, 3 – SDNS; HAZ – height for age Z-score).
Figure 2. Z-score of the body weight in patients with dif-
ferent clinical variations of nephrotic syndrome (1 – SSNS, 
2 – FRNS, 3 – SDNS; BAZ – BMI for age Z-score).
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Leukemoid reactions (evident leukocytosis with an in-
creased content of neutrophilic leukocytes) were reported 
in 12 children of group 1 against the administration of the 
maximum prednisolone dose.
Corticosteroid therapy frequently resulted in the gas-
tro-intestinal events in the patients under study: there were 
signs of reactive pancreatitis, in the children of group 2 – 
exacerbation of pancreatitis with pain syndrome and an 
increase in the serum amylase. Exacerbation of chronic 
gastroduodenitis was observed in 33.3% of patients of 
group 1; gastric erosion was diagnosed in one case. Half 
of the children had liver damage (diffuse hepatic changes 
in ultrasound examination, an increase in transaminases 
in blood serum).
Arterial hypertension, disturbances of the carbohydrate 
metabolism and infections were less frequently diagnosed 
complications in the patients with nephrotic syndrome 
during their stay in the hospital (Fig. 3).
Obesity and overweight, reactive pancreatitis, chronic 
gastroduodenitis and liver damage were more often diag-
nosed in the children with non-frequently relapsing ne-
phrotic syndrome (Fig. 3).
Unlike them, the patients with FRNS and SDNS more 
frequently developed arterial hypertension and Cushing’s 
syndrome. There were no statistically significant differ-
ences between the groups.
The performed study showed the incidence of adverse 
side effects in the children receiving the GCS therapy and 
the structure of pediatric morbidity patterns after its com-
pletion. Long-term administration of high doses of GCS 
resulted in the development of Cushing’s syndrome. The 
incidence of these adverse side effects was higher than 
in other studies (Hahn et al. 2015, Ishikura et al. 2015); 
this is probably due to the fact that the occurrence of the 
adverse side effects was analyzed during administration 
of the maximum dose of prednisolone. The children of 
group 2, who were monitored during the period of the 
prolonged remission of nephrotic syndrome, were neither 
overweight, nor obese; they had no growth failure. The 
study of the adverse side effects depending on whether 
GCS were or were not administered allowed assessing the 
prognostic value of therapeutic side effects and their im-
pact on the child’s health.
Gastro-intestinal disorders were frequently diagnosed 
in the patients of group 1; they included development of 
reactive pancreatitis, chronic gastroduodenitis, and he-
patic disorders. The incidence of the above disorders was 
higher compared to the data of other researchers (Bek-
murzayeva and Poleshchyuk 2012, Hahn et al. 2015). The 
complaints of a child and all the changes revealed in clin-
ical-laboratory and instrumentation tests were taken into 
account. Pancreatic and hepatic disorders were transient 
and were corrected after the end of the GCS therapy. Two 
patients had signs of chronic gastroduodenitis after the 
end of GCS therapy. This fact was one of the reasons for 
developing a criterion of the early diagnostics of adverse 
side effects in GCS therapy to perform targeted pharma-
cological correction of the conditions described above.
Leukemoid reactions detected in the children of group 
1 against the GCS administration appeared during the 
administration of the maximum hormone dose and dis-
appeared after the dose reduction; which did not require 
additional correction.
According to the clinical records, one child of group 1 
did not reveal complications of the GCS administration 
despite the “standard” dose of GCS. Though there was 
body weight gain in this case as well, it fell within the 
range of values normal for the given age and gender.
Foster et al. (2006) specified influence of the imme-
diate (within 6 months) and long-term (over 6 months) 
Figure 3. The incidence of the adverse side effects of corticosteroid therapy in patients with clinical variations of nephrotic syndrome.
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administration of GCS on the development of obesity in 
children with steroid-sensitive nephrotic syndrome (Fos-
ter et al. 2006). According to the present study results, 
non-administration of GCS for 6 months and over re-
sulted in the normalization of the body weight of a child. 
In long-term monitoring (up to 13 years), children with 
non-frequently relapsing nephrotic syndrome had neither 
excess body weight nor growth failure.
Blood pressure was measured and a blood glucose test 
was performed regularly in all children. Deviations of 
these parameters were detected only in a small number 
of patients.
In adults, GCS administration often results in steroid 
diabetes mellitus (Landyshev 2014, Strachunsky and Ko-
zlov 2001). In the performed studyб the episodes of hy-
perglycemia during the administration of high doses of 
GCS were reported only in 2 children.
There was a retrospective study of the adverse side ef-
fects of the GCS therapy by analyzing the clinical records 
findings, that is why the study did not include behavioral 
and sleep disorders that might also occur in children dur-
ing the GCS administration. All the children were exam-
ined by the ophthalmologist, but this examination did not 
involve intraocular pressure measurement. All the chil-
dren with nephrotic syndrome were given calcium and 
vitamin D preparations to prevent osteoporosis; an X-ray 
examination was performed if medically required, but no 
targeted examination was performed to reveal osteoporo-
sis in the patients.
The general recommendations on the management of 
patients receiving GCS orally include application of the 
minimal effective doses compliant with the therapeutical 
regimen (the alternating regimen, circadian rhythm of 
administration). If possible, it is necessary to reduce the 
dose of the preparation until the drug withdrawal (Beck 
et al. 2013). Rational nutrition with the sufficient protein 
content, increased intake of products rich in potassium 
(1.5–2 g/day), calcium and vitamin D, reduced intake of 
chlorides, maintenance of the normal body weight, reg-
ular physical exercise, depending on the general health 
status, are of great importance (Tsygin et al. 2006).
Potassium preparations (potassium chloride, potassi-
um and magnesium aspartates) should be administered 
to correct hypokalemia arising when administering high 
doses of corticosteroids.
Cholecalciferol (vitamin D3) (dosage 1000–30000 IU/
day) in combination with calcium preparations (dosage 
1000–1500 mg/day) should be prescribed to correct os-
teopenia and osteoporosis in children receiving corticos-
teroids (Clinical recommendations on medical care for 
children with nephrotic syndrome). This therapy should 
be administered simultaneously with prescribing GCS 
that are to be taken for a long term – for 3 months and 
over (Toroptsova 2014).
To prevent damage to the gastro-intestinal tract , pro-
ton pump inhibitors should be applied (Beck et al. 2013).
When GCS are administered for more than 10 days, the 
preparation should be withdrawn with the gradual dose 
reduction. Withdrawal regimens depend on the duration 
of CS administration. It is possible to reduce intake of 
prednisolone by 2.5–5 mg every 3–5 days (Beck et al. 
2013). Special care should be taken in reducing a pred-
nisolone daily dose to 10 mg and less. If the preparations 
have been applied for 2 weeks and longer throughout 
1.5–2 years, the patient’s status should be monitored un-
der stress after withdrawal of the preparations, and, when 
necessary, a protective therapy with GCS should be per-
formed (Beck et al. 2013).
There are no evidence-based data relating the ASE of 
GCS therapy specific for treatment of glomerulonephritis, 
but there is evidence relating to immunosuppression in 
kidney transplantation. Application of antibiotics to mini-
mize opportunistic infections and proton pump inhibitors 
to prevent peptic ulcers are the examples of the most com-
mon preventive measures (Beck et al. 2013).
Conclusion
Thus, glucocorticosteroid therapy of nephrotic syndrome 
in children resulted in the development of a large number 
of side effects. Adverse side effects, including the most 
commonly observed obesity and overweight, reactive pan-
creatitis, liver damage, Cushing’s syndrome, were reported 
in 94.4% of patients receiving glucocorticosteroid therapy 
for 6 months prior to the examination. After completion 
of the corticosteroid therapy (for 6 months and more), the 
signs of chronic gastroduodenitis were recorded in 15.4% 
of children; which might be ASE of the GCS therapy.
In addition to potassium and cholecalciferol prepara-
tions, proton pump inhibitors are recommended for use to 
prevent adverse side effects of GCS on the gastro-intesti-
nal tract in patients receiving the corticosteroid therapy.
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